Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease-Reference-Cited by-同舟云学术

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease

Published:2017-05 Issue:5 Volume:23 Page:833-839
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Ma Christopher,Fedorak Richard N.,Kaplan Gilaad G.,Dieleman Levinus A.,Devlin Shane M.,Stern Nathan,Kroeker Karen I.,Seow Cynthia H.,Leung Yvette,Novak Kerri L.,Halloran Brendan P.,Huang Vivian W.,Wong Karen,Blustein Philip K.,Ghosh Subrata,Panaccione Remo

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference30 articles.

1. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

2. The global burden of IBD: from 2015 to 2025

3. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

4. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

5. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years;Scientific Reports;2024-06-28

2. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

3. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data;Digestive and Liver Disease;2024-05

4. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study;Saudi Journal of Gastroenterology;2024-04-10

5. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years;2024-03-13